Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06392763
Status:
COMPLETED
Last Update Posted:
2024-04-30
First Post:
2024-04-26
Brief Title:
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This retrospective cohort study based on the French medico-administrative database SNDS evaluated the care pathway the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor CAR T cells CART-cells KYMRIAH or YESCARTA paediatric and young adult patients up to and including 25 years of age with acute lymphoblastic leukaemia ALL and adult patients 18 years of age or older with DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None